Friday, 16 October 2026European Markets

QUESTERRE ENERGY Stock Bullish By 15% In The Last 5 Sessions

Loading stream...

Questerre Energy (QEC.OL), listed on the Oslo Bors Benchmark Index, saw an impressive 15.24% surge this week amid overall market movements. This jump, which saw stocks rise from kr1.59 to kr1.83, marked a significant recovery following last week's general market decline of 0.29%. Despite the recent rebound, Questerre remains below its 52-week high of kr2.53.

Questerre's Position in Canada's Energy Industry

Questerre Energy shines in Canada's energy industry as a leading acquirer, explorer, and developer of non-conventional oil and gas projects. Notably, Questerre boasts substantial assets throughout the Kakwa region of central Alberta and owns oil shale stakes in Jordan.

Questerre's Financials

Questerre's trailing 12-month Earnings Per Share (EPS) thrive at kr0.17, yielding an approximate price-earnings ratio of 10.76. This metric suggests that investors currently pay roughly kr10.76 for every kr1 of annual earnings produced by Questerre, presenting them as a potential bargain compared to industry norms.

Return on Equity (ROE)

Questerre's trailing-year return on equity (ROE), which evaluates corporate profitability by depicting the return investors receive from their equity, resides at 3.18%.

Stock Performance

Questerre's recent stock price advancement puts it above both its 50-day moving average of kr1.68 and 200-day average of kr1.77. These indicators serve as positive signs for both investors and analysts. While its annual upper limit remains significantly lower, the current 52-week floor of kr1.45 is considerably higher than at this point in time.

Stochastic Oscillator Score

Questerre's stochastic oscillator score - a benchmark measuring overbought and oversold conditions in the stock market - places its shares in the oversold category. This score hints that the shares could rally as investors seize what may be an undervalued opportunity.

More news about QUESTERRE ENERGY (QEC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com